Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, Mediastinal (Thymic) Large B-Cell LymphomaNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C82.-C82.7C82.9C83.3C84.4C84.6C84.7C85.2C86.1C86.2C86.5C94.7-MeSHLymphoma, Large-Cell, AnaplasticLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, PeripheralSequenceSTUDY - levelChemotherapyChemo-substanceCisplatinGemcitabineMethylprednisoloneNivolumabOxaliplatinChemo-substanceCisplatinGemcitabineMethylprednisoloneNivolumabOxaliplatinChemo-substanceCisplatinGemcitabineMethylprednisoloneNivolumabOxaliplatinChemo-substanceCisplatinGemcitabineMethylprednisoloneNivolumabOxaliplatinNo. Substances123 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideSupportive substanceAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneFilgrastimFosaprepitantGranisetronMagnesiumMagnesium sulfatePegfilgrastimPotassium chlorideNo. Substances178Protocol classificationTherapy classificationalternativeStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseConsolidationTherapy intentioncurativepalliativeRisksAlopeciaAnemia Hb below 8g/dlConstipationDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHyperglycemiaHypertensionInfectionsMucositisNeuropathyNeutropeniaRenal FailureThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorGleeson MHeld GDiseaserezidivierendes (erstlinie mit Anthrazyklin) oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2, ECOG 0-2rezidivierendes oder fortschreitendes aggressives NHL, > 65 Jahre oder >18 mit HCT-Cl score > 2T-Zell-Lymphom, Stadium I-IV, ECOG 0-3OriginInternal Medicine I Saarland University Medical School, DSHNHL 2015-1The Royal Marsden NHS Foundation Trust, London and Surrey, UKProtocols in Revision 5 protocols foundProtocols under revision.Gemcitabine 1000 / Cisplatin 100 / Methylprednisolone 1000, T-cell Lymphoma (PID2354 V1.0)Study - Level - Gemcitabine 1000 / Oxaliplatin 100, Aggressive Non-Hodgkin Lymphoma (PID972 V1.0)Study - Level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, Cycle 1 (PID968 V1.2)Study - level - Nivolumab 240 / Gemcitabine 1000 / Oxaliplatin 100, diffuse large B-Non-Hodgkin Lymphoma, cycle 2+ (PID970 V1.2)Study - Level - Nivolumab 240, diffuse large B-Non-Hodgkin Lymphoma, consolidation (PID971 V1.1)
